$OTLK
Outlook Therapeutics, Inc. Common Stock
XNAS
Why is OTLK down today? It is at $1.00 (-2.43%), and our scanner flagged it 204 times on unusual volume this month. See the catalyst behind the move, real-time alerts the moment OTLK spikes, and full due diligence on OTLK — key stats, earnings, dilution and insider activity. Free.
Get free $OTLK alerts the moment volume spikes
Our scanner flagged $OTLK 204 times in the last 30 days. Create a free account to track $OTLK, build a watchlist, and get instant unusual-volume alerts — plus 5 free premium days, no card needed.
No card · 5 premium days · join 800+ traders
Key Stats
- Price
- $1.00
- Change today
- -2.43%
- Previous close
- $1.03
- 52-week range
- $0.161 – $3.39
- Market cap
- $124M
- Institutional own.
- 6.37%
- Total held
- 7.9%
- Tradeable float
- 111.3M 92% of shares · after 2% insiders + 6% institutions
- Short interest
- 11.2M ▼ -20% vs prior · as of 2026-07-15
- Short % of float
- 10.1%
- Days to cover
- 1.2d
- Avg daily volume
- 9.1M
- Next earnings
- Aug 13 · in 7d
- Exchange
- XNAS
- 5m
- 0.2x
- 15m
- 0.1x
- 1h
- 0.3x
- 1D
- 0.1x
Get free OTLK + market alerts in your inbox
The top plays and unusual-volume catches our scanner flags, emailed to you. No account needed.
No spam. Unsubscribe anytime. Not investment advice.
Why is $OTLK down today?
OTLK is one of today's most active names, trading on unusually heavy volume (live price and day move above). Our scanner has fired 3 unusual-volume and momentum alerts on OTLK today, peaking at 12.4x its normal volume.
Likely catalystAnnounces LYTENAVA™ FDA Approval as the First and Only FDA-Approved Ophthalmic Bevacizumab for the Treatment of Wet AMDReported Commercial Franchise Positioned to Establish a New Standard as an FDA-Approved Bevacizumab Therapy Across the Approximately $8.5 BillionReported enters one of the world's largest ophthalmology markets. The U.S. anti-VEGF retina market is estimated at approximately $8.5 billionReported adverse reaction (≥1%) reported in patients receiving LYTENAVA was conjunctival hemorrhage (4%), eye pain (2%), and vitreous floaters, from the latest SEC filing. Read it →Analyst data via Nasdaq. Not investment advice.
Insiders
Insiders buying8 open-market buys7 buys, 0 sells last 3 months (7/0 over 12 months)Show 9 recent transactionsMinimize 9 recent transactions
| Insider | Action | Shares | % of position | Owns after | Value | Date |
|---|---|---|---|---|---|---|
Sukhtian Faisal Ghiath Director | Bought (open market) | +95K 0.08% of company | added 76% | 221K | $100K at $1.05 | Jul 29, 26 |
Haddadin Yezan Munther Director | Bought (open market) | +29K 0.02% of company | added 78% | 66K | $24K at $0.830 | Jun 2, 26 |
Sukhtian Ghiath M. Director | Bought (open market) | +8.54M 7.1% of company | added 63% | 22.09M | $5.0M at $0.590 | May 28, 26 |
Sukhtian Faisal Ghiath Director | Bought (open market) | +122K 0.1% of company | added 100% | 126K | $50K at $0.410 | May 27, 26 |
Hilzinger Kurt J Director | Bought (open market) | +400K 0.3% of company | added 100% | 424K | $176K at $0.440 | May 26, 26 |
Thurman Randy H Director | Bought (open market) | +5K | added 100% | 6K | $2K at $0.430 | May 26, 26 |
Haddadin Yezan Munther Director | Bought (open market) | +34K 0.03% of company | added 100% | 37K | $15K at $0.440 | May 26, 26 |
Sukhtian Ghiath M. Director | Acquired (grant/award) | +4.29M 3.5% of company | added 46% | 13.55M | $6.0M at $1.40 | May 27, 25 |
Kenyon Lawrence A Officer | Bought (open market) | +5K | added 100% | 6K | $28K at $5.69 | Sep 26, 24 |
Recent Form-4 filings via Nasdaq. Open-market buys are the signal worth watching. Grants and automatic (10b5-1) sells are routine. “% of position” is the share of that insider’s own holding the trade moved. Not investment advice.
Dilution watch
Active shelfAt-the-market (ATM) offering active — the company can keep selling new shares into the market over time (ongoing). If $OTLK runs, these filings show who may be positioned to sell new or newly-registered shares into the move.
- At-the-market (ATM) program — sells new shares into the market gradually over time · About $100M in size
Sourced from SEC EDGAR filings (last 9 months); terms read straight from the filing text where available. Ongoing = an at-the-market (ATM) program still selling over time or a live shelf, so it can keep diluting; Completed = a one-time priced sale that already finished. A shelf (S-3) stays effective ~3 years. Form type signals dilution capacity, not an exact share count, and we can't confirm how much of a shelf or ATM remains unused. Not investment advice.
$OTLK Sentiment
NeutralBlend of news sentiment, today’s move, and community votes. Not investment advice.
$OTLK Activity
News, unusual-volume alerts, AI-trader trades and community chatter — the whole story, newest first.
OTLK stock FAQ
Why is $OTLK down today?
OTLK is one of today's most active names, trading on unusually heavy volume (live price and day move above). Our scanner has fired 3 unusual-volume and momentum alerts on OTLK today, peaking at 12.4x its normal volume.
What is the OTLK stock price today?
OTLK last traded at $1.00, down 2.43% on the day. The price and chart above update live during market hours (4 AM to 8 PM ET).
When does OTLK report earnings?
Outlook Therapeutics, Inc. Common Stock (OTLK) is next expected to report earnings on Thursday, August 13, 2026, about 7 days away. Earnings reports often cause large overnight gaps, so many traders manage risk around the date. The date can shift until the company officially confirms it.
Where can I see live OTLK alerts?
The OTLK Live Alerts panel on this page streams real-time unusual volume (RVOL), momentum, halt and 200-EMA alerts from our scanner the moment they fire. Our scanner has flagged OTLK 204 times in the last 30 days.
What exchange is OTLK on?
OTLK (Outlook Therapeutics, Inc. Common Stock) trades on XNAS, with a market cap of about $124M.
Is OTLK good for day trading?
That depends on your strategy and risk. Day traders look for volume, volatility and a clear trend. Use the live chart, RVOL alerts and 200-EMA context on this page to judge OTLK for yourself. This is not investment advice.
Live data from TheDesperateTrader scanner. Not investment advice.